<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00443612</url>
  </required_header>
  <id_info>
    <org_study_id>IRBEH_L_00702</org_study_id>
    <nct_id>NCT00443612</nct_id>
  </id_info>
  <brief_title>Irbesartan/Hydrochlorothiazide National Taiwan University Hospital Listing</brief_title>
  <official_title>A Randomized, Open Label, Cross-over Comparative Study of Irbesartan/Hydrochlorothiazide and Irbesartan in the Treatment of Mild to Moderate Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary:

        1. To compare the change in forearm vascular resistance following a 12-week regimen of
           irbesartan/hydrochlorothiazide versus irbesartan

        2. To assess changes of serum proinflammatory cytokine, markers of cardiovascular risks,
           oxidative stress and circulating adhesion molecule including thiobarbiturate acid
           reactive substances (TBARS), C-reactive protein (CRP), interleukin 6 (IL-6), and
           vascular cell adhesion molecule 1 (VCAM-1).

      Secondary:

        1. To compare the reduction in office blood pressure following a 12-week regimen of
           irbesartan/hydrochlorothiazide versus irbesartan

        2. To compare the response rate (defined as office Systolic blood pressure(SBP)/diastolic
           blood pressure (DBP) reduce more than 10mmHg from baseline), and BP controlled rate
           (defined as SBP&lt;140 mmHg and /or DBP&lt;90 mmHg)

        3. To ascertain the safety and tolerability of irbesartan / hydrochlorothiazide versus
           irbesartan when administered once daily

        4. To determine whether angiotensin II type 1 (AT-1) receptor gene polymorphisms (including
           A1166C gene with about 4% of the minor allele frequency in Chinese population and other
           single nucleotide polymorphisms with a higher frequency of about 10% of minor allele) is
           related to reduction of BP
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Forearm vascular resistance</measure>
    <time_frame>At baseline and end of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of serum TBARS, CRP, IL-6, and VCAM-1</measure>
    <time_frame>Throughout the study period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Office BP measurement of seated SBP and DBP</measure>
    <time_frame>At baseline and after 12-week treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Throughout the study period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Office BP measurement of seated SBP and DBP</measure>
    <time_frame>At baseline and after 12-week treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 weeks on treatment 1
2 week washout period
12 weeks on treatment 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 weeks on treatment 2
2 week washout period
12 weeks on treatment 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irbesartan/Hydrochlorothiazide</intervention_name>
    <description>Administration of irbesartan 150 mg/day + hydrochlorothiazide 12.5 mg</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irbesartan</intervention_name>
    <description>Administration of irbesartan 150 mg/day</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with mild to moderate hypertension with office diastolic BP (DBP) 90-109 mmHg
        and/or systolic BP (SBP) 140-179 mmHg before entering each treatment

        Exclusion Criteria:

          -  females: who are pregnant or breast feeding

          -  office DBP ≧ 110 mmHg or office SBP ≧ 180 mmHg

          -  history of significant cardiovascular diseases which include: acute myocardial
             infarction within six months or any ischemic heart disease requiring medication, or
             cerebrovascular disease

          -  history of significant renal diseases including: serum creatinine &gt; 3.0 mg/dl, or
             creatinine clearance &lt; 30 ml/min.

          -  severe biliary cirrhosis and cholestasis

          -  refractory hypokalemia, hypercalcemia

          -  history of autoimmune disease, collagen vascular disease, multiple drug allergies,
             bronchospastic disease or other malignancies requiring current medication

          -  hepatic disease as indicated by any of the following : Serum Glutamic Oxaloacetic
             Transaminase (SGOT) or Serum Glutamic Pyruvate Transaminase (SGPT) &gt;3 x upper limit of
             normal, or serum bilirubin &gt; 2 x upper limit of normal

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fern Lim</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2007</study_first_submitted>
  <study_first_submitted_qc>March 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2007</study_first_posted>
  <last_update_submitted>September 30, 2009</last_update_submitted>
  <last_update_submitted_qc>September 30, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2009</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irbesartan</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

